Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Conditions

• Non-Hodgkin's Lymphoma
• Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
• Ann Arbor Stage II Follicular Lymphoma
• Ann Arbor Stage II Nodal Marginal Zone Lymphoma
• Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
• Ann Arbor Stage III Follicular Lymphoma
• Ann Arbor Stage III Nodal Marginal Zone Lymphoma
• Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
• Ann Arbor Stage IV Follicular Lymphoma
• Ann Arbor Stage IV Nodal Marginal Zone Lymphoma
• Grade 1 Follicular Lymphoma
• Grade 2 Follicular Lymphoma
• Grade 3a Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Stage II Splenic Marginal Zone Lymphoma
• Stage III Splenic Marginal Zone Lymphoma
• Stage IV Splenic Marginal Zone Lymphoma

Interventions

• DRUG: Ibrutinib
• BIOLOGICAL: Obinutuzumab
• OTHER: Laboratory Biomarker Analysis

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

• [object Object]
• [object Object]